Posted: 2013-03-14, 10:42 quick weight loss product
New draft guidelines from NICE (The National Institute of Clinical Excellence) Zhen De Shou recommend for the first time that Tamoxifen should be offered to women at high-risk of breast cancer. Breast cancer is extremely common, affecting 1 in 10 women in the UK.
Only approximately 1% of the female population will be considered high-risk and offered the preventative drug. These are women with multiple other members of the family having had breast cancer or P57 related cancers and women who carry a gene that puts them at high risk (e.g. BRCA1 or BRCA2). Currently, high-risk women are offered early breast screening with mammograms or MRI scans to pick up cancers early or surgery to remove their breast tissue. Surgery reduces the likelihood of developing a cancer by 90-95%, however, it is a major undertaking for all women and not an option that all women wish to take.
Tamoxifen is a drug traditionally used for women with breast Slim Forte Double Power cancer to prevent the disease recurring. In about half of high-risk women, taking Tamoxifen will reduce their Pai You Ji level of risk by 70%. Prof Gareth Evans, one of Genesis’ key researchers was involved in drafting the guidance and believes that Tamoxifen can be used as an alternative to [url=http://www.eachslim.com/reduce-
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum You cannot attach files in this forum You can download files in this forum